Abstract
Prolyl oligopeptidase (PO) interacts with α-synuclein in vitro. It is a weak interaction that induces a nucleation prone conformation of α-synuclein. PO accelerates aggregation and fibril formation of α-synuclein in a process that can be reversed by specific inhibitors and is also influenced by an impairing mutation in the PO active site. There is evidence that PO and α-synuclein also interact intracellularly, especially in conditions where the expression of α-synuclein is high. Specific PO inhibitors reduce the number of cells with α-synuclein inclusions in a cellular model of Parkinsons disease. If these interactions also exist in the human brain, PO may be a target for the treatment of Parkinsons disease and other synucleinopathies. Whether PO also contributes to the normal physiological functions of α-synuclein remains an open question, but there are some intriguing parallels between the proposed functions of both proteins that deserve further investigation.
Keywords: Amyloid, peptidase, neurodegeneration, neurotransmission, Parkinson's disease, prolyl oligopeptidase, synuclein, Synucleinopathies, Multiple system atrophy, Dictyostelium discoidum, Alzheimers disease, Z-pro-prolinal, UAMC-00021, Tubulin
CNS & Neurological Disorders - Drug Targets
Title: Interaction of Prolyl Oligopeptidase with α-Synuclein
Volume: 10 Issue: 3
Author(s): Anne-Marie Lambeir
Affiliation:
Keywords: Amyloid, peptidase, neurodegeneration, neurotransmission, Parkinson's disease, prolyl oligopeptidase, synuclein, Synucleinopathies, Multiple system atrophy, Dictyostelium discoidum, Alzheimers disease, Z-pro-prolinal, UAMC-00021, Tubulin
Abstract: Prolyl oligopeptidase (PO) interacts with α-synuclein in vitro. It is a weak interaction that induces a nucleation prone conformation of α-synuclein. PO accelerates aggregation and fibril formation of α-synuclein in a process that can be reversed by specific inhibitors and is also influenced by an impairing mutation in the PO active site. There is evidence that PO and α-synuclein also interact intracellularly, especially in conditions where the expression of α-synuclein is high. Specific PO inhibitors reduce the number of cells with α-synuclein inclusions in a cellular model of Parkinsons disease. If these interactions also exist in the human brain, PO may be a target for the treatment of Parkinsons disease and other synucleinopathies. Whether PO also contributes to the normal physiological functions of α-synuclein remains an open question, but there are some intriguing parallels between the proposed functions of both proteins that deserve further investigation.
Export Options
About this article
Cite this article as:
Lambeir Anne-Marie, Interaction of Prolyl Oligopeptidase with α-Synuclein, CNS & Neurological Disorders - Drug Targets 2011; 10 (3) . https://dx.doi.org/10.2174/187152711794653878
DOI https://dx.doi.org/10.2174/187152711794653878 |
Print ISSN 1871-5273 |
Publisher Name Bentham Science Publisher |
Online ISSN 1996-3181 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Novel Anticancer Agents and Targets: Recent Advances and Future Perspectives
Mini-Reviews in Medicinal Chemistry Targeting Transient Receptor Potential Channels in Cardiometabolic Diseases and Myocardial Ischemia Reperfusion Injury
Current Drug Targets Natural Compounds as Anticancer Agents Targeting DNA Topoisomerases
Current Genomics In Vivo Roles of CDC25 Phosphatases: Biological Insight into the Anti-Cancer Therapeutic Targets
Anti-Cancer Agents in Medicinal Chemistry Quantitative Structure-Activity Relationship Studies: Understanding the Mechanism of Tyrosine Kinase Inhibition
Current Enzyme Inhibition Physiological and Pathological Functions of Acid-Sensing Ion Channels in the Central Nervous System
Current Drug Targets An Update on the Other Telomerase Inhibitors: Non-G-Quadruplex Interactive Agent, Non-Antisense, Non-Reverse Transcriptase Telomerase Inhibitors
Medicinal Chemistry Reviews - Online (Discontinued) The Synthesis of Nano-Doxorubicin and its Anticancer Effect
Anti-Cancer Agents in Medicinal Chemistry Vascularization of Biomaterials for Bone Tissue Engineering: Current Approaches and Major Challenges
Current Angiogenesis (Discontinued) Subject Index To Volume 7
Current Drug Targets G and C Iterons and Strings in MicroRNAs Should be Important in Regulation of mRNAs<sup>†</sup>
MicroRNA Development and Clinical Application of Peptide-Based Radiopharmaceuticals
Current Pharmaceutical Design The Therapeutic Aspects of the Endocannabinoid System (ECS) for Cancer and their Development: From Nature to Laboratory
Current Pharmaceutical Design Exosomal microRNAs as Potentially Useful Tools in Cancer Biomarker Discovery
Recent Patents on Biomarkers Keeping A Breast of Recent Developments in Cancer Metabolism
Current Drug Targets Mechanisms of ERK1/2 Regulation by Seven-Transmembrane-Domain Receptors
Current Pharmaceutical Design Membrane Tyrosine Kinase Receptors are an Important Target for the Therapy of Acute Myeloid Leukemia
Current Cancer Therapy Reviews Gene Therapy for Parkinsons and Alzheimers Diseases: from the Bench to Clinical Trials
Current Pharmaceutical Design Molecular Markers of Glioblastoma and the Potential for Integration with Imaging: the Future for Assigning Prognosis and Best Treatment Strategy
Current Molecular Imaging (Discontinued) Current Status and Perspectives in Peptide Receptor Radiation Therapy
Current Pharmaceutical Design